comparemela.com

Latest Breaking News On - Elyad oncology sa - Page 1 : comparemela.com

Celyad Oncology SA: Publication of a Rectified Transparency Notification Received From Fortress Investment Group LLC Seite 1

15.09.2023 - Regulatory News: Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major . Seite 1

Bruxelles capitaleUnited kingdomFrance generalCompany brusselsFortress investment groupRegulatory newsBelgian lawCelyad oncologyCelyad oncology aktieElyad oncology sa

Celyad Oncology Reports First Half 2023 Financial Results

Georges Rawadi was appointed Chief Executive Officer as from April 27, 2023Celyad Oncology has received approximately EUR 9.8m in private placement.

United statesCity ofUnited kingdomWalloon regionWaals gewestMont saint guibertRegion flamandeCaroline lonezGeorges rawadiDavid georgesWorld oncology cell therapy congressInternational conference on lymphocyte engineeringWrd communicationsBusiness developmentExchange commissionDartmouth college

Celyad Oncology to announce full year 2022 financial

MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company.

Mont saint guibertWaals gewestNew yorkUnited statesDavid georgesCaroline lonezExchange commissionBusiness developmentWrd communicationsBelgium fixedBelgium mobilePrivate securities litigation reform actCelyad oncologyAnnual reportOncology contactsNasdaq cyad

Celyad Oncology Announces FDA Lifts Clinical Hold of

MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company.

United statesMont saint guibertWaals gewestNew yorkWalloon regionSara zelkovicCharles morrisMerck co incExchange commissionCommunications investor relationsMerck sharp dohmeDrug administrationChief medical officerMerck sharpPrivate securities litigation reform actCelyad oncology

Celyad Oncology to Announce First Half 2022 Financial

MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company.

Mont saint guibertWaals gewestNew yorkUnited statesWalloon regionLincoln parkSara zelkovicLincoln park capital fundExchange commissionCommunications investor relationsCelyad oncologyPrivate securities litigation reform actAnnual reportMedia contactsNasdaq cyadElyad oncology sa

vimarsana © 2020. All Rights Reserved.